Patents Examined by Karlheinz R. Skowronek
  • Patent number: 10314921
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 11, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
  • Patent number: 10316063
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10314880
    Abstract: The present invention relates to ready to dilute injectable formulations of bortezomib comprising bortezomib, non-aqueous solvents enhancing the solubility and pH modifying agent.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 11, 2019
    Inventors: P. Kanteepan, Sagar Laxmanbhai Vekariya, Jayanta Kumar Mandal, Sandip P. Mehta
  • Patent number: 10316062
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10314776
    Abstract: The present invention relates to the field of dental care, in particular, to a dental care product such as toothpaste (dentifrice), prophylactic paste, tooth powder, tooth polish, tooth gel, chewing gum, candy, lozenge, mouthwash, whitening strip, coated dental floss, coated toothbrush, paint-on gel, varnish, veneer, and tube, syringe or dental tray comprising a gel or paste, mouthwash, whitening strips and trays for whitening teeth, wherein the product comprises mineral particles such as crystals and a compound, preferably, a protein capable of forming a matrix which is a hydrogel, wherein the product comprises a fluorophore. The mineral particles may comprise, e.g., calcium phosphate, preferably, hydroxyapatite, preferably, in crystalline form. The protein matrix may comprise, e.g., a self-assembling peptide. The product also comprises a fluorophore, which may be a fluorescent amino acid residue of the protein matrix.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: June 11, 2019
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek, Karl-Heinz Kunzelmann
  • Patent number: 10307509
    Abstract: The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: June 4, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Andreas Goessl, Katarzyna Gorna
  • Patent number: 10308677
    Abstract: An improved method for coupling carboxylic acids and amines is disclosed that includes the steps of combining a hyper-acid sensitive linker connecting an amine and a resin, a carboxylic acid, a carbodiimide, an activator additive, and a base, and carrying out the activation and coupling at a temperature greater than 30° C.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 4, 2019
    Assignee: CEM Corporation
    Inventors: Jonathan M. Collins, Sandeep Kumar Singh
  • Patent number: 10308681
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrolysate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrolysate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrolysate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 4, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10308682
    Abstract: Disclosed herein are fibrillar molecular aggregates, which are morphologically and phenotypically similar to oligomers of aberrant proteins. The molecular aggregates, formed by self-assembly of small hydrophobic molecules, prevent the growth of microtubules. This unprecedented mechanism of “self-assembly to interfere with self-organization” allows inhibition of the growth of cancer cells.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Brandeis University
    Inventors: Bing Xu, Yi Kuang
  • Patent number: 10308699
    Abstract: The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: June 4, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Noriyuki Kawahata, Vincent Guerlavais, Manoj Samant
  • Patent number: 10301352
    Abstract: We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.
    Type: Grant
    Filed: August 23, 2014
    Date of Patent: May 28, 2019
    Assignee: UNIWERSYTET WARSZAWSKI
    Inventors: Aleksandra Misicka-Kęsik, Dagmara Tymecka, Bartlomiej Fedorczyk, Piotr Sosnowski, Beata Wileńska, Ewa Witkowska, Patrick Ladam, Gerard Y. Perret, Anna Starzec
  • Patent number: 10301357
    Abstract: The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 28, 2019
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Vassilios Papadopoulos, Yasaman Aghazadeh, Jinjiang Fan
  • Patent number: 10301356
    Abstract: The present invention described herein relates to the composition that interact with molecules that suppress the immune system.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 28, 2019
    Assignee: CANIMGUIDE THERAPEUTICS AB
    Inventor: Leif Håkansson
  • Patent number: 10292997
    Abstract: The present invention relates to compositions and methods to improve the microenvironments in and around the wound in an effort to enhance healing. Specifically, the present invention comprises application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or cinnamon extracts including but not limited to MHCP. The media is applied to the wound to stimulate the viable cells in the wound bed and the adjacent cells in the periphery of the wound to proliferate and grow into the wound in order to achieve wound closure.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 21, 2019
    Inventor: Ella Lindenbaum
  • Patent number: 10287328
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 14, 2019
    Assignee: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • Patent number: 10286034
    Abstract: Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 10266612
    Abstract: A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells while maintaining their pluripotency/multipotency.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 23, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Victor Nurcombe, Simon Cool
  • Patent number: 10258695
    Abstract: Methods and reagents for enhancing cellular uptake of a cargo molecule by covalently bonding optionally-substituted fluorenyl groups to the cargo molecules, where cellular uptake includes at least partial uptake into the cytosol. Useful fluorenylation reagents include those of formula: and salts thereof where variables are as defined. Cargo molecules include peptides and proteins. Also provided are fluorenylated cargo molecules, including fluorenylated peptides and proteins.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 16, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Kristen A. Andersen
  • Patent number: 10258074
    Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: April 16, 2019
    Assignee: Wisonsin Alumni Research Foundation
    Inventors: Denise M. Ney, Mark R. Etzel
  • Patent number: 10258573
    Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Amphastar Pharmaceuticals, Inc.
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang